2024
Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Galderisi A, Kariyawasam D, Stoupa A, Quoc A, Pinto G, Viaud M, Brabant S, Beltrand J, Polak M, Samara-Boustani D. Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring. European Journal Of Endocrinology 2024, 190: l7-l7. PMID: 38668689, DOI: 10.1093/ejendo/lvae042.Peer-Reviewed Original Research
2023
Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Galderisi A, Kariyawasam D, Stoupa A, Quoc A, Pinto G, Viaud M, Brabant S, Beltrand J, Polak M, Samara-Boustani D. Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring. European Journal Of Endocrinology 2023, 189: k19-k24. PMID: 37952170, DOI: 10.1093/ejendo/lvad147.Peer-Reviewed Original ResearchConceptsClassical congenital adrenal hyperplasiaClassical CAHCongenital adrenal hyperplasiaContinuous glucose monitoringLower cortisol concentrationsGlucose patternsAdrenal hyperplasiaCortisol concentrationsGlucose monitoringFludrocortisone replacement therapySensor glucose valuesHydrocortisone doseAcute illnessAsymptomatic hypoglycemiaWhole cohortNighttime hypoglycemiaReplacement therapyPercentage of timeObservational studyGlucose profilesGlycemic patternsSerial measuresGlucose valuesDaily cortisolHypoglycemia
2022
Glucose-to-lactate ratio and neurodevelopment in infants with hypoxic-ischemic encephalopathy: an observational study
Galderisi A, Tordin M, Suppiej A, Cainelli E, Baraldi E, Trevisanuto D. Glucose-to-lactate ratio and neurodevelopment in infants with hypoxic-ischemic encephalopathy: an observational study. European Journal Of Pediatrics 2022, 182: 837-844. PMID: 36484862, PMCID: PMC9899169, DOI: 10.1007/s00431-022-04694-3.Peer-Reviewed Original ResearchConceptsHypoxic-ischemic encephalopathyTherapeutic hypothermiaNeurodevelopmental outcomesLactate ratioDay 1Severe hypoxic-ischemic encephalopathyNew risk markerSevere hypoNeonatal hypoglycemiaMetabolic outcomesRisk markersObservational studyMetabolic variablesDay 2InfantsLactate concentrationEncephalopathyLactate kineticsNeurodevelopmentMetabolic fuelsNeonatesStrongest predictorHypothermiaOutcomesGlucose
2021
Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants
Galderisi A, Trevisanuto D, Russo C, Hall R, Bruschettini M. Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants. 2021, 2021: cd013309. PMID: 34931697, PMCID: PMC8690212, DOI: 10.1002/14651858.cd013309.pub3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRisk of hypoglycaemiaUse of CGMContinuous glucose monitoringPreterm infantsIntermittent modalitiesRisk ratioEffects of CGMLong-term neurodevelopmental impairmentGlucose monitoringEfficacy of CGMCare Group (EPOC) criteriaPreterm infants 1Cochrane Effective PracticePrevention of morbidityClinical trials databasesLong-term outcomesConfidence intervalsPreterm infant mortalitySafety of CGMImprecision of estimatesFixed-effects modelAdverse neurodevelopmentGRADE approachNeurodevelopmental outcomesDATA COLLECTION
2020
Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants
Galderisi A, Bruschettini M, Russo C, Hall R, Trevisanuto D. Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants. 2020, 12: cd013309. PMID: 33348448, PMCID: PMC8092644, DOI: 10.1002/14651858.cd013309.pub2.Peer-Reviewed Original ResearchConceptsPreterm infantsContinuous glucose monitoringGlycemic measuresRisk ratioIntermittent modalitiesLong-term neurodevelopmental impairmentGlucose monitoringCare Group (EPOC) criteriaCochrane Central RegisterCochrane Effective PracticePrevention of morbidityQuasi-randomized trialStandard search strategyClinical trials databasesLong-term outcomesPreterm infant mortalityAllied Health LiteratureUse of CGMImprecision of estimatesFixed-effects modelCochrane NeonatalAdverse neurodevelopmentCentral RegisterGRADE approachControlled Trials
2019
Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
Sherr J, Buckingham BA, Forlenza G, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett L, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology & Therapeutics 2019, 22: 174-184. PMID: 31596130, PMCID: PMC7047109, DOI: 10.1089/dia.2019.0286.Peer-Reviewed Original ResearchConceptsDaily physical activityPhysical activityFree-living conditionsPercentage timeMultiple daily injectionsType 1 diabetesRespective age groupsCohort of participantsHybrid closed-loop systemPrimary endpointDaily injectionsEligible participantsClosed-loop studiesPercentage of timeTherapy phaseInvestigational deviceNights of useAge groupsSensor glucoseType 1Home settingDlSignificant decreaseUsual routineAdults
2016
Randomized Summer Camp Crossover Trial in 5- to 9-Year-Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe
Del Favero S, Boscari F, Messori M, Rabbone I, Bonfanti R, Sabbion A, Iafusco D, Schiaffini R, Visentin R, Calore R, Moncada Y, Galasso S, Galderisi A, Vallone V, Di Palma F, Losiouk E, Lanzola G, Tinti D, Rigamonti A, Marigliano M, Zanfardino A, Rapini N, Avogaro A, Chernavvsky D, Magni L, Cobelli C, Bruttomesso D. Randomized Summer Camp Crossover Trial in 5- to 9-Year-Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe. Diabetes Care 2016, 39: 1180-1185. PMID: 27208335, DOI: 10.2337/dc15-2815.Peer-Reviewed Original ResearchConceptsSensor-augmented pumpCrossover trialMean glucoseArtificial pancreasType 1 diabetesArtificial Pancreas ProjectWearable artificial pancreasAP trialOlder childrenTrialsHypoglycemiaYoung childrenChildrenPancreasOvernight timeSignificant changesGlucoseDaysDiabetesOutpatientsResearch designThreefold reduction